Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofogliflozin Effects on Endogenous Glucose Production and Insulin Clearance in Type 2 Diabetes
jRCTs031180117Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tofogliflozin in type 2 diabetes mellitus (T2DM), sponsored by Kowa Company, Ltd. Primary endpoint: Insulin clearance after tofogliflozin administration. Started Nov 2018; status: completed.
02
Drugs
tofogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031180117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180117.